|本期目录/Table of Contents|

[1]况里杉,周向东,廖秀清,等.糖尿病与肺癌EGFR靶向治疗相关性的研究进展[J].中华肺部疾病杂志,2020,(03):403-406.[doi:10.3877/cma.j.issn.1674-6902.2020.03.027]
点击复制

糖尿病与肺癌EGFR靶向治疗相关性的研究进展(PDF)

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:
期数:
2020年03期
页码:
403-406
栏目:
综述
出版日期:
2020-06-20

文章信息/Info

Title:
-
作者:
况里杉1; 周向东2; 廖秀清1; 张孝彬1; 唐 楠1
408000 重庆,重庆市涪陵中心医院呼吸内科1 400038 重庆,陆军(第三)军医大学第一附属医院呼吸内科2
Author(s):
-
关键词:
支气管肺癌;  糖尿病;  表皮生长因子受体;  靶向治疗
Keywords:
-
分类号:
R734.2
DOI:
10.3877/cma.j.issn.1674-6902.2020.03.027
摘要:
-
Abstract:
-

参考文献/References:

1 Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2): 87-108.
2 Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
3 Guariguata L, Whiting DR, Hambleton I, et al. Global estimates of diabetes prevalence for 2013 and projections for 2035[J]. Diabetes Res Clin Pract, 2014, 103(2): 137-149.
4 Tseng CH. Diabetes but not insulin increases the risk of lung cancer: a Taiwanese population-based study[J]. PLoS One, 2014, 9(7): e101553.
5 Lee JY, Jeon I, Lee JM, et al. Diabetes mellitus as an independent risk factor for lung cancer: a meta-analysis of observational studies[J]. Eur J Cancer, 2013, 49(10): 2411-2423.
6 Tseng CH. Metformin and lung cancer risk in patients with type 2 diabetes mellitus[J]. Oncotarget, 2017, 8(25): 41132-41142.
7 Zhu N, Zhang Y, Gong YI, et al. Metformin and lung cancer risk of patients with type 2 diabetes mellitus: A meta-analysis[J]. Biomed Rep, 2015, 3(2): 235-241.
8 Sakoda LC, Ferrara A, Achacoso NS, et al. Metformin use and lung cancer risk in patients with diabetes[J]. Cancer Prev Res(Phila), 2015, 8(2): 174-179.
9 Luo J, Hendryx M, Qi L, et al. Pre-existing diabetes and lung cancer prognosis[J]. Br J Cancer, 2016, 115(1): 76-79.
10 Tian RH, Zhang YG, Wu Z, et al. Effects of metformin on survival outcomes of lung cancer patients with type 2 diabetes mellitus: a meta-analysis[J]. Clin Transl Oncol, 2016, 18(6): 641-649.
11 Cao X, Wen ZS, Wang XD, et al. The Clinical Effect of Metformin on the Survival of Lung Cancer Patients with Diabetes: A Comprehensive Systematic Review and Meta-analysis of Retrospective Studies[J]. J Cancer, 2017, 8(13): 2532-2541.
12 Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions[J]. J Clin Oncol, 2005, 23(11): 2556-2568.
13 Lamb YN, Scott LJ. Osimertinib: A Review in T790M-Positive Advanced Non-Small Cell Lung Cancer[J]. Target Oncol, 2017, 12(4): 555-562.
14 Costa DB, Huberman MS. Improvement of type 2 diabetes in a lung cancer patient treated with Erlotinib[J]. Diabetes Care, 2006, 29(7): 1711.
15 Brooks MB. Erlotinib appears to produce prolonged remission of insulin requiring type 2 diabetes associated with metabolic syndrome and chronic kidney disease[J]. Achieving Best Practice, 2012, 12(2): 87-90.
16 Brooks MB. Erlotinib and gefitinib, epidermal growth factor receptor kinase inhibitors, may treat non-cancer-related tumor necrosis factor-α mediated inflammatory diseases[J]. Oncologist, 2013, 18(1): e3-5.
17 黄 恬, 蔡 稀, 钟 玲. 厄洛替尼减轻STZ诱导的糖尿病肾病模型大鼠的肾损伤[J]. 中国病理生理杂志, 2017, 33(8): 1460-1466.
18 孙 琦, 王胜男, 李玉秀, 等. 吉非替尼对糖尿病大鼠胰岛素敏感性的影响[J]. 中华医学杂志, 2009, 89(48): 3441-3443.
19 Prada PO, Saad MJ. Tyrosine kinase inhibitors as novel drugs for the treatment of diabetes[J]. Expert Opin Investig Drugs, 2013, 22(6): 751-763.
20 杨 翠, 徐 瑜, 胡义德. 二甲双胍对肺腺癌耐厄洛替尼细胞株A549ER的耐药逆转作用[J/CD]. 中华肺部疾病杂志(电子版), 2014, 7(5): 507-511.
21 Li L, Han R, Xiao H, et al. Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal[J]. Clin Cancer Res, 2014, 20(10): 2714-2726.
22 Morgillo F, Sasso FC, Della CCM, et al. Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines[J]. Clin Cancer Res, 2013, 19(13): 3508-3519.
23 Ashinuma H, Takiguchi Y, Kitazono S, et al. Antiproliferative action of metformin in human lung cancer cell lines[J]. Oncol Rep, 2012, 28(1): 8-14.
24 Wu N, Gu C, Gu H, et al. Metformin induces apoptosis of lung cancer cells through activating JNK/p38 MAPK pathway and GADD153[J]. Neoplasma, 2011, 58(6): 482-490.
25 周寒丽, 耿健雄, 张 华. 二甲双胍抗肿瘤机制的研究进展[J]. 现代肿瘤医学, 2015, 23(12): 1760-1763.
26 Li KL, Li L, Zhang P, et al. A Multicenter Double-blind Phase Ⅱ Study of Metformin With Gefitinib as First-line Therapy of Locally Advanced Non-Small-cell Lung Cancer[J]. Clin Lung Cancer, 2017, 18(3): 340-343.
27 Fasano M, Della CCM, Capuano A, et al. A multicenter, open-label phase Ⅱ study of metformin with erlotinib in second-line therapy of stage Ⅳ non-small-cell lung cancer patients: treatment rationale and protocol dynamics of the METAL trial[J]. Clin Lung Cancer, 2015, 16(1): 57-59.
28 Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism[J]. Nature, 2001, 414(6865): 799-806.
29 Stamos J, Sliwkowski MX, Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor[J]. J Biol Chem, 2002, 277(48): 46265-46272.
30 Ballotti R, Lammers R, Scimeca JC, et al. Intermolecular transphosphorylation between insulin receptors and EGF-insulin receptor chimerae[J]. EMBO J, 1989, 8(11): 3303-3309.
31 Gogg S, Smith U. Epidermal growth factor and transforming growth factor alpha mimic the effects of insulin in human fat cells and augment downstream signaling in insulin resistance[J]. J Biol Chem, 2002, 277(39): 36045-36051.
32 孙栋勋, 蔡志毅. EGFR/PI3K/Akt 细胞信号传导通路与肿瘤[J]. 检验医学, 2014, 29(7): 768-773.
33 Kang X, Kong F, Wu X, et al. High glucose promotes tumor invasion and increases metastasis-associated protein expression in human lung epithelial cells by upregulating heme oxygenase-1 via reactive oxygen species or the TGF-β1/PI3K/Akt signaling pathway[J]. Cell Physiol Biochem, 2015, 35(3): 1008-1022.
34 张欣霞, 陈 婷, 涂 盛, 等. 胰岛素信号通路与肿瘤风险相关性的研究进展[J]. 浙江中医药大学学报, 2015, 39(5): 418-422.
35 Memmott RM, Mercado JR, Maier CR, et al. Metformin prevents tobacco carcinogen-induced lung tumorigenesis[J]. Cancer Prev Res(Phila), 2010, 3(9): 1066-1076.
36 Xiao Z, Gaertner S, Morresi-Hauf A, et al. Metformin Triggers Autophagy to Attenuate Drug-Induced Apoptosis in NSCLC Cells, with Minor Effects on Tumors of Diabetic Patients[J]. Neoplasia, 2017, 19(5): 385-395.
37 刘 喆. 胰岛素生长因子-1受体信号通路与肺癌的研究进展[J]. 中国肺癌杂志, 2010, 13(6): 642-647.
38 Hurbin A, Wislez M, Busser B, et al. Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma[J]. J Pathol, 2011, 225(1): 83-95.
39 Yeo CD, Kim YA, Lee HY, et al. Inhibiting IGF-1R attenuates cell proliferation and VEGF production in IGF-1R over-expressing EGFR mutant non-small cell lung cancer cells[J]. Exp Lung Res, 2017, 43(1): 29-37.
40 Hussmann D, Madsen AT, Jakobsen KR, et al. IGF1R depletion facilitates MET-amplification as mechanism of acquired resistance to erlotinib in HCC827 NSCLC cells[J]. Oncotarget, 2017, 8(20): 33300-33315.
41 Suda K, Mizuuchi H, Sato K, et al. The insulin-like growth factor 1 receptor causes acquired resistance to erlotinib in lung cancer cells with the wild-type epidermal growth factor receptor[J]. Int J Cancer, 2014, 135(4): 1002-1006.
42 Li L, Gu X, Yue J, et al. Acquisition of EGFR TKI resistance and EMT phenotype is linked with activation of IGF1R/NF-κB pathway in EGFR-mutant NSCLC[J]. Oncotarget, 2017, 8(54): 92240-92253.
43 Langer CJ, Novello S, Park K, et al. Randomized, phase Ⅲ trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer[J]. J Clin Oncol, 2014, 32(19): 2059-2066.
44 吴国明, 钱桂生. 非小细胞肺癌靶向治疗研究进展及新理念[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(4): 405-408.
45 孙晓远, 刘 斌, 蒋捍东, 等. 不同EGFR突变位点晚期非小细胞肺癌的临床特征及对靶向药物治疗反应分析[J/CD]. 中华肺部疾病杂志(电子版), 2018, 11(3): 289-294.

备注/Memo

备注/Memo:
基金项目: 2018重庆市医学科研计划项目(2018MSXM139)
更新日期/Last Update: 2020-06-20